For its first phocean edition, BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Over 1,150 attendees from over 35 countries attended BioFIT’s 8th edition: 120+ exhibitors, 70 speakers, 16 conferences and 4 projects elected as the most innovative in their categories were gathered in Marseille at Parc Chanot on December 10th and 11th.
TrakCel: New at the helm
AppointmentsCo-founder Fiona Withey is the new Chief Executive Officer of TrakCel, a software developer of orchestration systems for advanced therapies. Co-founder Ravi Nalliah was appointed to the role of Chief Strategy Officer.
Applied Photophysics: Permanent head
AppointmentsApplied Photophysics Limited, active in biophysical characterization of biomolecules, has appointed Tim Flanagan as Chief Executive Officer and member of the Board of Directors.
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug
Latest NewsDiabetes combo improves regeneration of beta cells
Latest NewsUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas.
JAKPot for treating bone loss
Latest NewsResearchers report that JAK inhibitors – a class of approved anti-inflammatory drugs – prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Review BioFIT 2019: A great first edition in Marseille
Sponsored PublicationsFor its first phocean edition, BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Over 1,150 attendees from over 35 countries attended BioFIT’s 8th edition: 120+ exhibitors, 70 speakers, 16 conferences and 4 projects elected as the most innovative in their categories were gathered in Marseille at Parc Chanot on December 10th and 11th.
Mereo BioPharma raise money to back Phase III trials
Latest NewsMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
Stilla raises €20m in series B financing round
Latest NewsFrench Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing.
BIH scientists optimise CRISPR gene scissors
Latest NewsTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises €25m in Series A round
Latest NewsDutch biotech Azafaros B.V. has closed a €25m Series A financing round.